EGFR and non-small cell lung carcinoma: The EGFR exon 20 p.T790M mutation confers drug resistance to first-generation EGFR TKIs, and it has been shown to occur in 1–2% of treatment-naïve EGFR-mutated NSCLC patients [14, 15].